bluuebunny/crossref_metadata_2025 huggingface dataset:
Externally validated machine learning algorithm accurately predicts medial tibial stress syndrome in military trainees: a multicohort study
Authors: Shaw Angus , Newman Phil , Witchalls Jeremy , Hedger Tristan
Published: June 2023

Objectives

Medial tibial stress syndrome (MTSS) is a common musculoskeletal injury in both sporting and military settings. No reliable treatments exist, and reoccurrence rates are high. Prevention of MTSS is critical to reducing operational burden. Therefore, this study aimed to build a decision-making model to predict the individual risk of MTSS within officer cadets and test the external validity of the model on a separate military population.

Design

Prospective cohort study.

Methods

This study collected a suite of key variables previously established for predicting MTSS. Data were obtained from 107 cadets (34 women and 73 men). A follow-up survey was conducted at 3 months to determine MTSS diagnoses. Six ensemble learning algorithms were deployed and trained five times on random stratified samples of 75% of the dataset. The resultant algorithms were tested on the remaining 25% of the dataset, with models then compared for accuracy. The most accurate new algorithm was tested on an unrelated data sample of 123 Australian Navy recruits to establish external validity of the model.

Results

Calibrated random forest modelling was the most accurate in identifying a diagnosis of MTSS; (area under curve (AUC)=98%, classification accuracy (CA)=96%). External validation on a sample of Navy recruits resulted in comparable accuracy; (AUC=95%, CA=94%). When the model was tested on the combined datasets, similar accuracy was achieved; (AUC=92%, CA=91%).

Conclusion

This model is highly accurate in predicting those who will develop MTSS. The model provides important preventive capacity which should be trialled as a risk management intervention.
Lugeon test: new insights into calculated hydraulic conductivity
Authors: Zoorabadi Mahdi
Published: June 2023

While the Lugeon test was initially designed to aid in determining the grouting needs of dam foundations in fractured rock, its outcomes have been utilized by geotechnical engineers and hydrogeologists to estimate the hydraulic conductivity. Most of the practitioners use the long-established relation of 1 Lu ≈ 1 × 10
−7
 m s
−1
to calculate the hydraulic conductivity based on the determined Lugeon value. However, this relationship does not cover all the potential boundary conditions encountered in field conditions where the Lugeon test is applied, and the consequences on the estimated hydraulic conductivity are poorly understood. This paper aims to address this issue by revisiting existing mathematical formulations to calculate the hydraulic conductivity from the Lugeon test under the various boundary conditions. The paper also examines how the flow conditions and length of test intervals impact the recorded Lu and hydraulic conductivity values. It was found that the long-stablished relationship of 1 Lu ≈ 1 × 10
−7
 m s
−1
and the equation presented in the commonly used reference of the Code of Practice for Site Investigation (BS 5930:1999 + A2:2010) only present one of the potential boundary conditions for the Lugeon test.
The Effect of the Interface Layer on the Electronic Parameters of the Light Emitting Electrochemical Cell (LEC) Device Based on Iridium (III) Complex that Calculated by Different Methods
Authors: Havare Ali Kemal , Alsaeedi Mona Sunaydih
Published: June 2023

We report a calculation of the electronic parameters and some optical measurement results of a light-emitting electrochemical cell (LEC), one of the most basic forms of electroluminescent films by modifying 4-(4-methoxy-N-naphthalen-1-ylanilino) benzoic acid (MA) as hole injection layer doped with an emissive layer that is ionic transition metal complex (Ir[dF(CF3)ppy]2(dtbpy))PF6-(Ir-iTMC). The electronic parameters of LEC device were computed using three different methods; Cheung and Cheung’s, Conventional Schottky and Norde, to evaluate the ideality factor (n), the barrier height (

ϕ

) and the series resistance (Rs) of the LEC device. The formation on indium tin oxide (ITO) substrate was analyzed by Atomic Force Microscopy (AFM). The HOMO-LUMO energy level and electronic charge distribution of the MA molecule were computed theoretically using Chemissian software. The MA’s HOMO-LUMO energy level is determined to be EHOMO = −5.27 eV and ELUMO = −1.40 eV. The ITO surface has been modified with the Self-Assembled Monolayers (SAM) technique as an interlayer to improve the surface working function by simplifying hole injection from the ITO anode to the Hole Transport Layer (HTL) in the LEC. The Ir- iTMC complexes containing Π-conjugated bridging ligand shown better external quantum efficiency (EQE), reaching to 1.49%. The max luminance values of the bare-LEC and LEC-MA are measured as 145 cd m−2 and 1240 cd m−2, respectively.
The Feasibility of Tungsten-Doped VO2 Films on Soda-Lime Glass with Low Thermal Budget by High Density Plasma Source for Smart Windows
Authors: Wang Ding-Yeong , Lin Kuei-Chih , Chen Yong-Chang , Juan Pi-Chun
Published: June 2023

Thermochromic W-doped VO2 thin films on soda-lime glass are successfully fabricated by co-sputtering technique using a high density plasma source, which is equipped by high power impulse magnetron sputtering (HIPIMS). A post-rapid thermal annealing of 500 °C is performed for the purpose of low thermal budget. The effect of doping amount of tungsten on thermochromic properties such as transmittance and transition temperature are addressed. The transition temperature can be lower down to 30 °C with a small amount of 4.5% tungsten added in VO2 nanocrystals. A solar regulation efficiency, ΔTsol = 10% is achieved at thicker TiO2 thickness. The competition of secondary phase of V2WO7.5 and oxygen-rich phase of V2O5 under different O2/Ar ratio is studied. The crystalline behavior of monoclinic phase is examined by X-ray diffraction (XRD) pattern and high resolution transmission electron microscope (HR-TEM). The good endurance property ensures the feasible use for the energy-saving applications.
Excited State Dynamics of Undoped and Eu3+-doped TbAl3(BO3)4 Crystals
Authors: Ruggieri Silvia , Ceccon Leonardo , Bettinelli Marco , Piccinelli Fabio
Published: June 2023

The room temperature luminescence spectra and emission decay curves of undoped and Eu3+-doped TbAl3(BO3)4 crystals, grown using the flux growth technique, are presented and discussed. The experimental results show that excitation of the Tb3+ levels gives rise to 5D0 emission from the Eu3+ ion, and therefore non-radiative energy transfer is operative involving the two ions. Analysis of the experimental data indicates that the excitation of the Tb3+ donor ion gives rise to diffusion limited migration of the energy in the 5D4 level of the Tb3+ subset of cations, followed by the energy transfer process populating the 5D0 level of Eu3+. Upon increasing the concentration of the Eu3+ acceptor, the mainly green emission intensity and the decay time of the 5D4 level decrease, whilst the red emission of 5D0 becomes dominant. The experimental data are interpreted on the basis of the trigonal huntite-type structure of the double borate crystals under investigation.
Association between Changes in Plasma Metabolism and Clinical Outcomes of Sepsis
Authors: Li Xin , Yin Zhongnan , Yan Wei , Wang Meng , Chang Chun , Guo Chenglin , Xue Lixiang , Zhou Qingtao , Sun Yongchang
Published: June 2023

Current prognostic biomarkers for sepsis have limited sensitivity and specificity. This study aimed to investigate dynamic lipid metabolomics and their association with septic immune response and clinical outcomes of sepsis. This prospective cohort study included patients with sepsis who met the Sepsis 3.0 criteria. On hospitalization days 1 (D1) and 7 (D7), plasma samples were collected, and patients underwent liquid chromatography with tandem mass spectrometry. A total of 40 patients were enrolled in the study, 24 (60%) of whom were men. The median age of the enrolled patients was 81 (68–84) years. Thirty-one (77.5%) patients had a primary infection site of the lung. Participants were allocated to the survivor (25 cases) and nonsurvivor (15 cases) groups based on their 28-day survival status. Ultimately, a total of 113 lipids were detected in plasma samples on D 1 and D 7, of which 42 lipids were most abundant in plasma samples. The nonsurvival group had significantly lower lipid expression levels in lysophosphatidylcholine (LysoPC) (16 : 0, 17 : 0,18 : 0) and 18 : 1 SM than those in the survival group (

p
<
 
0.05

) on D7–D1. The correlation analysis showed that D7–D1 16 : 0 LysoPC (r = 0.367,

p
=
0.036

),17 : 0 LysoPC (r = 0.389,

p
=
0.025

) and 18 : 0 LysoPC(r = 0.472,

p
=
0.006

) levels were positively correlated with the percentage of CD3+ T cell in the D7–D1. Plasma LysoPC and SM changes may serve as prognostic biomarkers for sepsis, and lipid metabolism may play a role in septic immune disturbances.
Gas Production Potential in Geothermal-Energy-Enhanced CH4–CO2 Swapping Processes
Authors: Guo Boyun , Zhang Peng
Published: June 2023

Carbon capture and storage has become a practice to reduce the greenhouse effect of carbon dioxide (CO2) on the global climate. Recent studies have generated increasing concerns about CO2 leakage from underground structures. This has called for more research on CH4–CO2 swapping in natural gas hydrate (NGH) reservoirs to lock CO2 in a solid state in underground structures. Because the CH4–CO2 swapping is too slow to be efficient, this study proposes to use geothermal energy to accelerate the process. This paper presents a technical feasibility analysis of using geothermal energy to assist CH4–CO2 swapping for simultaneously storing CO2 in NGH reservoirs and producing the dissociated natural gas. Mathematical models were developed to compute heat transfer from geothermal zones to NGH reservoirs. A case study was carried out using the data from an NGH reservoir in the Shenhu area, Northern South China Sea. The result of the case study indicates that heat conduction dictates the heat transfer process when the heat convection flow rate is less than 0.01 m3/s over a heat-releasing borehole length of 2,000 m. Heat convection can significantly accelerate the heat transfer inside the gas hydrate reservoir. The 15°C (designed gas hydrate dissociation temperature in the studied case) heat front will propagate to the upper and lower boundaries of the gas hydrate reservoir (39 ft or 12 m) in 220 days by heat conduction only. This time can be shortened to 140 days with the aid of a fluid convection rate of 0.005 m3/s. Geothermal heating can significantly increase the initial productivity of wells in heated gas hydrate reservoirs in CO2 swapping processes. When the gas hydrate reservoir is heated from 6 to 16°C, the fold of increase is expected to exceed five in the studied case. This study shows that CH4–CO2 swapping process using geothermal stimulation is a promising method for producing natural gas and locking CO2 permanently in NGH reservoirs. Further studies should first focus on investigations of the effect of CO2-hydrate formation on the CO2 mass transfer inside reservoirs.
Supplementary Data 1 from The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Authors: Desmots Fabienne , Rossille Delphine , Roussel Mikael , Pangault Céline , Louarn Laetitia , De Saint Jore Mylène , Le Gouill Steven , Bouabdallah Krimo , Delwail Vincent , Gressin Remy , Cornillon Jérôme , Damaj Gandhi , Maisonneuve Hervé , Damotte Diane , Kraeber-Bodere Françoise , Lamy Thierry , Parrens Marie-Cécile , Milpied Noël , Fest Thierry
Published: June 2023

supplemental methods, tables and figures
Supplementary Table S3: Clinical trials of A2AR inhibitors from ENPP1 Immunobiology as a Therapeutic Target
Authors: Ruiz-Fernández de Córdoba Borja , Martínez-Monge Rafael , Lecanda Fernando
Published: June 2023

Clinical trials of A2AR inhibitors
Supplementary Table S2: Clinical trials of CD39 inhibitors from ENPP1 Immunobiology as a Therapeutic Target
Authors: Ruiz-Fernández de Córdoba Borja , Martínez-Monge Rafael , Lecanda Fernando
Published: June 2023

Clinical trials of CD39 inhibitors
Supplementary Table S1: Clinical Trials of ENPP1 inhibitors from ENPP1 Immunobiology as a Therapeutic Target
Authors: Ruiz-Fernández de Córdoba Borja , Martínez-Monge Rafael , Lecanda Fernando
Published: June 2023

Clinical Trials of ENPP1 inhibitors
Supplementary Methods and Key Resources Table 1 from Proteostasis Modulation in Germline Missense von Hippel Lindau Disease
Authors: Chittiboina Prashant , Mandal Debjani , Bugarini Alejandro , Asuzu David T. , Mullaney Dustin , Mastorakos Panagiotis , Stoica Stefan , Alvarez Reinier , Scott Gretchen , Maric Dragan , Elkahloun Abdel , Zhuang Zhengping , Chew Emily Y. , Yang Chunzhang , Linehan Marston , Lonser Russell R.
Published: June 2023

Supplementary Methods and Key Resources Table
Censoring rules 3 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Authors: Hong David S. , Postow Michael , Chmielowski Bartosz , Sullivan Ryan , Patnaik Amita , Cohen Ezra E.W. , Shapiro Geoffrey , Steuer Conor , Gutierrez Martin , Yeckes-Rodin Heather , Ilaria Robert , O'Connell Brenda , Peng Joanna , Peng Guangbin , Zizlsperger Nora , Tolcher Anthony , Wolchok Jedd D.
Published: June 2023

Study IPI-549-01 progression-free survival censoring rules for efficacy analyses
Figure S1 from Proteostasis Modulation in Germline Missense von Hippel Lindau Disease
Authors: Chittiboina Prashant , Mandal Debjani , Bugarini Alejandro , Asuzu David T. , Mullaney Dustin , Mastorakos Panagiotis , Stoica Stefan , Alvarez Reinier , Scott Gretchen , Maric Dragan , Elkahloun Abdel , Zhuang Zhengping , Chew Emily Y. , Yang Chunzhang , Linehan Marston , Lonser Russell R.
Published: June 2023

Figure S1
Supplementary Tables S1-S14 from Proinflammatory Macrophage Activation by the Polysialic Acid-Siglec-16 Axis Is Linked to Increased Survival of Patients with Glioblastoma
Authors: Thiesler Hauke , Gretenkort Lina , Hoffmeister Leonie , Albers Iris , Ohlmeier Luisa , Röckle Iris , Verhagen Andrea , Banan Rouzbeh , Köpcke Nora , Krönke Nicole , Feuerhake Friedrich , Behling Felix , Barrantes-Freer Alonso , Mielke Dorothee , Rohde Veit , Hong Bujung , Varki Ajit , Schwabe Kerstin , Krauss Joachim K. , Stadelmann Christine , Hartmann Christian , Hildebrandt Herbert
Published: June 2023

Supplementary Table S1.Demographic and clinical parameters of GB patient cohorts.Supplementary Table S2.Characteristics of the two cohorts of n = 70 (MHH) and n = 100 (UMG) GB patients stratified for the presence of a functional SIGLEC16 allele (A) or for the occurrence of polySia on tumor cells (B).Supplementary Table S3.Cox proportional hazards regression analysis of covariates for SIGLEC16 and polySia status in relation to OS (MHH and UMG cohorts combined).Supplementary Table S4.Median age of GB cases stratified for SIGLEC16 genotype and polySia on tumor cells.Supplementary Table S5.OS analysis of GB cases receiving (A) or not receiving gross total resection (B) stratified for SIGLEC16 genotype and polySia on tumor cells (MHH and UMG cohorts combined).Supplementary Table S6.OS analysis of GB cases receiving (A) or not receiving chemotherapy (B) stratified for SIGLEC16 genotype and polySia on tumor cells (MHH cohort only).Supplementary Table S7.OS analysis of GB cases receiving gross total resection and chemotherapy stratified for SIGLEC16 genotype and polySia on tumor cells (MHH and UMG cohorts combined, n=101).Supplementary Table S8.OS analysis of IDH-wildtype GB cases (UMG cohort) stratified for SIGLEC16 genotype and polySia on tumor cells.Supplementary Table S9.OS analysis of UMG cohort stratified for MGMT gene promoter methylation and SIGLEC16 genotype, polySia on tumor cells, CD163 and CD74 status.Supplementary Table S10.Characteristics of the two cohorts of n = 70 (MHH) and n = 100 (UMG) GB patients stratified for CD74low and CD74high.Supplementary Table S11. Median age at resection of GB cases stratified for CD163 to CD68 (A) or CD74 to IBA1 ratios (B) alone or in combination with the SIGLEC16 genotype.Supplementary Table S12. OS analysis of GB cases receiving (A) or not receiving gross total resection (B) stratified for CD163 to CD68 or CD74 to IBA1 ratios alone or in combination with the SIGLEC16 genotype (MHH and UMG cohorts combined).Supplementary Table S13. OS analysis of GB cases receiving (A) or not receiving chemotherapy (B) stratified for CD163 to CD68 or CD74 to IBA1 ratios alone or in combination with the SIGLEC16 genotype (MHH cohort only).Supplementary Table S14.OS analysis of GB cases receiving both gross total resection and chemotherapy stratified for CD163 to CD68 or CD74 to IBA1 ratios alone or in combination with the SIGLEC16 genotype (MHH and UMG cohorts combined, n=101).
Supplementary Figure S6 from Proinflammatory Macrophage Activation by the Polysialic Acid-Siglec-16 Axis Is Linked to Increased Survival of Patients with Glioblastoma
Authors: Thiesler Hauke , Gretenkort Lina , Hoffmeister Leonie , Albers Iris , Ohlmeier Luisa , Röckle Iris , Verhagen Andrea , Banan Rouzbeh , Köpcke Nora , Krönke Nicole , Feuerhake Friedrich , Behling Felix , Barrantes-Freer Alonso , Mielke Dorothee , Rohde Veit , Hong Bujung , Varki Ajit , Schwabe Kerstin , Krauss Joachim K. , Stadelmann Christine , Hartmann Christian , Hildebrandt Herbert
Published: June 2023

Antibody array detection of cytokines and chemokines
Supplementary Table S3 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
Authors: Kottschade Lisa A. , Pond Gregory Russell , Olszanski Anthony J. , Zakharia Yousef , Domingo-Musibay Evidio , Hauke Ralph J. , Curti Brendan D. , Schober Sarah , Milhem Mohammed M. , Block Matthew Stephen , Hieken Tina , McWilliams Robert R.
Published: June 2023

Related Treatment Adverse Events
Supplementary Table S2 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
Authors: Kottschade Lisa A. , Pond Gregory Russell , Olszanski Anthony J. , Zakharia Yousef , Domingo-Musibay Evidio , Hauke Ralph J. , Curti Brendan D. , Schober Sarah , Milhem Mohammed M. , Block Matthew Stephen , Hieken Tina , McWilliams Robert R.
Published: June 2023

Grade 3+ Adverse Events
Supplementary Figure S4 from Proinflammatory Macrophage Activation by the Polysialic Acid-Siglec-16 Axis Is Linked to Increased Survival of Patients with Glioblastoma
Authors: Thiesler Hauke , Gretenkort Lina , Hoffmeister Leonie , Albers Iris , Ohlmeier Luisa , Röckle Iris , Verhagen Andrea , Banan Rouzbeh , Köpcke Nora , Krönke Nicole , Feuerhake Friedrich , Behling Felix , Barrantes-Freer Alonso , Mielke Dorothee , Rohde Veit , Hong Bujung , Varki Ajit , Schwabe Kerstin , Krauss Joachim K. , Stadelmann Christine , Hartmann Christian , Hildebrandt Herbert
Published: June 2023

PolySia on GB tumor cells is associated with NCAM
Supplementary Figure S3 from Proinflammatory Macrophage Activation by the Polysialic Acid-Siglec-16 Axis Is Linked to Increased Survival of Patients with Glioblastoma
Authors: Thiesler Hauke , Gretenkort Lina , Hoffmeister Leonie , Albers Iris , Ohlmeier Luisa , Röckle Iris , Verhagen Andrea , Banan Rouzbeh , Köpcke Nora , Krönke Nicole , Feuerhake Friedrich , Behling Felix , Barrantes-Freer Alonso , Mielke Dorothee , Rohde Veit , Hong Bujung , Varki Ajit , Schwabe Kerstin , Krauss Joachim K. , Stadelmann Christine , Hartmann Christian , Hildebrandt Herbert
Published: June 2023

PolySia is not associated with CD3- or CD34-positive cells
TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
Authors: Sivapalan Lavanya , Iams Wade T. , Belcaid Zineb , Scott Susan C. , Niknafs Noushin , Balan Archana , White James R. , Kopparapu Prasad , Cann Christopher , Landon Blair V. , Pereira Gavin , Velculescu Victor E. , Hann Christine L. , Lovly Christine M. , Anagnostou Valsamo
Published: June 2023

Supplementary Tables S1-S9
Supplementary Figure S1 from Proinflammatory Macrophage Activation by the Polysialic Acid-Siglec-16 Axis Is Linked to Increased Survival of Patients with Glioblastoma
Authors: Thiesler Hauke , Gretenkort Lina , Hoffmeister Leonie , Albers Iris , Ohlmeier Luisa , Röckle Iris , Verhagen Andrea , Banan Rouzbeh , Köpcke Nora , Krönke Nicole , Feuerhake Friedrich , Behling Felix , Barrantes-Freer Alonso , Mielke Dorothee , Rohde Veit , Hong Bujung , Varki Ajit , Schwabe Kerstin , Krauss Joachim K. , Stadelmann Christine , Hartmann Christian , Hildebrandt Herbert
Published: June 2023

PolySia is associated with GFAP-positive cells
Fig S8 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
Authors: Sivapalan Lavanya , Iams Wade T. , Belcaid Zineb , Scott Susan C. , Niknafs Noushin , Balan Archana , White James R. , Kopparapu Prasad , Cann Christopher , Landon Blair V. , Pereira Gavin , Velculescu Victor E. , Hann Christine L. , Lovly Christine M. , Anagnostou Valsamo
Published: June 2023

Longitudinal changes in cfTL were re-analyzed for each patient, considering all plasma variants independent of origin. Survival analyses revealed that CH-unfiltered ctDNA responses were not associated with either (A) overall survival-OS or (B) progression-free survival-PFS. Comparison between CH-unfiltered ctDNA responses and radiographic assessments (PR/CR vs SD/PD/MR) in these patients revealed that CH-unfiltered responses we not predictive of (C) OS at 12 and (D) 36 months, and PFS at (E) 3 and (F) 12 months, compared to best overall radiographic responses.
Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Authors: Antoniotti Carlotta , Boccaccino Alessandra , Seitz Robert , Giordano Mirella , Catteau Aurélie , Rossini Daniele , Pietrantonio Filippo , Salvatore Lisa , McGregor Kimberly , Bergamo Francesca , Conca Veronica , Leonetti Simone , Morano Federica , Papiani Giorgio , Tamburini Emiliano , Bensi Maria , Murgioni Sabina , Ross Douglas Teller , Passardi Alessandro , Boquet Isabelle , Nielsen Tyler J. , Galon Jérôme , Varga Matthew Gordon , Schweitzer Brock L. , Cremolini Chiara
Published: June 2023

Kaplan Meier estimates of progression-free survival in the pMMR population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b).Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.
Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Authors: Antoniotti Carlotta , Boccaccino Alessandra , Seitz Robert , Giordano Mirella , Catteau Aurélie , Rossini Daniele , Pietrantonio Filippo , Salvatore Lisa , McGregor Kimberly , Bergamo Francesca , Conca Veronica , Leonetti Simone , Morano Federica , Papiani Giorgio , Tamburini Emiliano , Bensi Maria , Murgioni Sabina , Ross Douglas Teller , Passardi Alessandro , Boquet Isabelle , Nielsen Tyler J. , Galon Jérôme , Varga Matthew Gordon , Schweitzer Brock L. , Cremolini Chiara
Published: June 2023

Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b).Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.
Fig S5 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
Authors: Sivapalan Lavanya , Iams Wade T. , Belcaid Zineb , Scott Susan C. , Niknafs Noushin , Balan Archana , White James R. , Kopparapu Prasad , Cann Christopher , Landon Blair V. , Pereira Gavin , Velculescu Victor E. , Hann Christine L. , Lovly Christine M. , Anagnostou Valsamo
Published: June 2023

(A) Overall, 27 patients had cell-free tumor load (cfTL) detected using tumor-derived sequence alterations, of which 20 patients also had evaluable plasma aneuploidy (PA)-based responses. Comparison between ctDNA responses determined using mutation-based and plasma aneuploidy-based responses in these 20 patients revealed significant concordance (p < 0.001, Fisher’s exact test). (B) Concordance was also observed between complete elimination of cfTL based on tumor-derived sequence alterations and plasma aneuploidy dynamics in these patients (p < 0.001, Fisher’s exact test). For these comparisons, plasma aneuploidy dynamics were assessed using a binarized classification of PA scores (PA score > 4.90 indicative of tumor aneuploidy, PA score <4.90 indicative of normal ploidy): PA undetectable (normal ploidy across all timepoints analyzed), PA response (aneuploidy detected at baseline or T1 sampling followed by a reduction to normal ploidy by final sampling), PA response followed by recrudescence (aneuploidy detected at baseline and final sampling with a reduction to normal ploidy at intermediate timepoints), PA progression (aneuploidy detected across all timepoints analyzed). (C) A logistic regression model combining both mutation-based and aneuploidy-based ctDNA responses in these 20 patients demonstrated that the combination of both sequence and structural dynamics outperformed either metric for the prediction of overall radiographic response (Combined model AUC = 0.90, Sequence alterations AUC = 0.85, Structural Alterations AUC = 0.74). (D-E) Further analyses of molecular responses derived from mutation-based analyses of cfTL changes in 27 patients with evaluable tumor-derived mutation trends demonstrated significant associations with both overall (OS) and progression-free (PFS) survival (log-rank p = 0.02 and p < 0.0001, respectively), independent of treatment modality (Chemotherapy vs immunotherapy-containing regimens). (F-G) cfTL elimination according to mutation-based analyses was also predictive of both OS and PFS (log-rank p = 0.01 and P < 0.0001, respectively). (H-I) Similarly, PA-based ctDNA responses showed significant associations with both OS (p =0.003) and PFS (log-rank p=0.001).
Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Authors: Antoniotti Carlotta , Boccaccino Alessandra , Seitz Robert , Giordano Mirella , Catteau Aurélie , Rossini Daniele , Pietrantonio Filippo , Salvatore Lisa , McGregor Kimberly , Bergamo Francesca , Conca Veronica , Leonetti Simone , Morano Federica , Papiani Giorgio , Tamburini Emiliano , Bensi Maria , Murgioni Sabina , Ross Douglas Teller , Passardi Alessandro , Boquet Isabelle , Nielsen Tyler J. , Galon Jérôme , Varga Matthew Gordon , Schweitzer Brock L. , Cremolini Chiara
Published: June 2023

Consort diagram of the study.Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.
Supplementary Table S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Authors: Lozano-Rabella Maria , Garcia-Garijo Andrea , Palomero Jara , Yuste-Estevanez Anna , Erhard Florian , Farriol-Duran Roc , Martín-Liberal Juan , Ochoa-de-Olza Maria , Matos Ignacio , Gartner Jared J. , Ghosh Michael , Canals Francesc , Vidal August , Piulats Josep Maria , Matías-Guiu Xavier , Brana Irene , Muñoz-Couselo Eva , Garralda Elena , Schlosser Andreas , Gros Alena
Published: June 2023

Show patient characteristics and relevant experimental information
Fig S1 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
Authors: Sivapalan Lavanya , Iams Wade T. , Belcaid Zineb , Scott Susan C. , Niknafs Noushin , Balan Archana , White James R. , Kopparapu Prasad , Cann Christopher , Landon Blair V. , Pereira Gavin , Velculescu Victor E. , Hann Christine L. , Lovly Christine M. , Anagnostou Valsamo
Published: June 2023

Schematic summarizing the branched logic used to determine the origin of sequence alterations identified in plasma NGS. Variants representing lung cancer hotspots were classified as tumor-derived, independent of their presence in matched WBC DNA NGS. Variants with a variant allele fraction (VAF) >25% in all WBC DNA and plasma samples from a patient were classified as germline. Alterations that were detected in matched WBC DNA sequencing or in the canonical clonal hematopoiesis (CH) gene DNMT3A were classified as CH-derived. For all variants detected in plasma using TEC-Seq but not in matched WBC DNA samples (based on a threshold of >3 supermutants), we performed an additional evaluation of their supermutant counts in the WBC DNA sequence data to exclude potential CH origin. Plasma variants with a supermutant count of >1 in matched WBC DNA TEC-Seq data were classified as CH-derived and alterations with a matched WBC DNA supermutant count of 0 were assigned a tumor-derived origin.
Table S7 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors
Authors: Toker Joseph , Iorgulescu J. Bryan , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: June 2023

Genes enriched in NEAT1-high glioblastoma tumor cells
Figure S4 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Authors: Sperger Jamie M. , Helzer Kyle T. , Stahlfeld Charlotte N. , Jiang Dawei , Singh Anupama , Kaufmann Katherine R. , Niles David J. , Heninger Erika , Rydzewski Nicholas R. , Wang Liguo , Wang Liewei , Yang Rendong , Ren Yanan , Engle Jonathan W. , Huang Peng , Kyriakopoulos Christos E. , Slovin Susan F. , Soule Howard R. , Zhao Shuang G. , Kohli Manish , Tagawa Scott T. , Cai Weibo , Dehm Scott M. , Lang Joshua M.
Published: June 2023

Figure S4. Biodistribution Study
Table S4 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors
Authors: Toker Joseph , Iorgulescu J. Bryan , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: June 2023

Glioblastoma patient characteristics (GSE121810)
Figure S3 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Authors: Sperger Jamie M. , Helzer Kyle T. , Stahlfeld Charlotte N. , Jiang Dawei , Singh Anupama , Kaufmann Katherine R. , Niles David J. , Heninger Erika , Rydzewski Nicholas R. , Wang Liguo , Wang Liewei , Yang Rendong , Ren Yanan , Engle Jonathan W. , Huang Peng , Kyriakopoulos Christos E. , Slovin Susan F. , Soule Howard R. , Zhao Shuang G. , Kohli Manish , Tagawa Scott T. , Cai Weibo , Dehm Scott M. , Lang Joshua M.
Published: June 2023

Figure S3. Scatter plot of gene expression for genes shown in Figure 3D isolated from matched anti-EPCAM vs anti-TROP-2 captured CTCs at the same timepoint.
Figure S2 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Authors: Sperger Jamie M. , Helzer Kyle T. , Stahlfeld Charlotte N. , Jiang Dawei , Singh Anupama , Kaufmann Katherine R. , Niles David J. , Heninger Erika , Rydzewski Nicholas R. , Wang Liguo , Wang Liewei , Yang Rendong , Ren Yanan , Engle Jonathan W. , Huang Peng , Kyriakopoulos Christos E. , Slovin Susan F. , Soule Howard R. , Zhao Shuang G. , Kohli Manish , Tagawa Scott T. , Cai Weibo , Dehm Scott M. , Lang Joshua M.
Published: June 2023

Figure S2. Capture Efficiency of TROP-2 Expressing Cell Lines.
Supplementary Fig. 6 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors
Authors: Toker Joseph , Iorgulescu J. Bryan , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: June 2023

Supplementary Fig. 6 NEAT1 expression in tumor-associated macrophages is associated with TNF-alpha signaling.
Supplementary Fig. 4 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors
Authors: Toker Joseph , Iorgulescu J. Bryan , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: June 2023

Supplementary Fig. 4 NEAT1 counts are reduced in formalin-fixed paraffin-embedded (FFPE) tissues compared to freshfrozen tissues.
Supplementary Fig. 2 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors
Authors: Toker Joseph , Iorgulescu J. Bryan , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: June 2023

Supplementary Fig. 2 NEAT1 expression is associated with the interferon-gamma response in melanoma.
Supplementary Fig. 1 from Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors
Authors: Toker Joseph , Iorgulescu J. Bryan , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: June 2023

Supplementary Fig. 1 Analysis of lncRNAs associated with patient response to ICB.
Figure S6 from Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
Authors: Horowitch Brooke , Lee Daniel Y. , Ding Min , Martinez-Morilla Sandra , Aung Thazin Nwe , Ouerghi Feriel , Wang Xueting , Wei Wei , Damsky William , Sznol Mario , Kluger Harriet , Rimm David L. , Ishizuka Jeffrey J.
Published: June 2023

Supplemental Figure 6: Western blots for A375, Mel JuSo, and YUSIK cell lines after acute and chronic IFN stimulation.
Figure S4 from Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
Authors: Horowitch Brooke , Lee Daniel Y. , Ding Min , Martinez-Morilla Sandra , Aung Thazin Nwe , Ouerghi Feriel , Wang Xueting , Wei Wei , Damsky William , Sznol Mario , Kluger Harriet , Rimm David L. , Ishizuka Jeffrey J.
Published: June 2023

Supplemental Figure 4: STAT1 in the nuclear compartment consistently predicts ICI response and survival but not nuclear pSTAT1Y701 or tumor/stromal PD-L1
Figure S2 from Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
Authors: Horowitch Brooke , Lee Daniel Y. , Ding Min , Martinez-Morilla Sandra , Aung Thazin Nwe , Ouerghi Feriel , Wang Xueting , Wei Wei , Damsky William , Sznol Mario , Kluger Harriet , Rimm David L. , Ishizuka Jeffrey J.
Published: June 2023

Supplemental Figure 2: Receiver operator curve analyses to validate median AQUA score cutpoints
Data from ENPP1 Immunobiology as a Therapeutic Target
Authors: Ruiz-Fernández de Córdoba Borja , Martínez-Monge Rafael , Lecanda Fernando
Published: June 2023

Abstract
ENPP1 (ecto-nucleotide pyrophosphatase/phosphodiesterase) participates in the hydrolysis of different purine nucleotides in an array of physiologic processes. However, ENPP1 is frequently overexpressed in local relapses and tumor metastases, which are associated with poor prognosis and survival in a range of solid tumors. ENPP1 promotes an immunosuppressive tumor microenvironment (TME) by tilting the balance of ATP/adenosine (Ado) in conjunction with other components (CD38, CD39/ENTPD1, and CD73/NT5E). Moreover, ENPP1 intersects with the stimulator of interferon genes (STING), impairing its robust immune response through the hydrolysis of the effector 2´,3´-cyclic GMP–AMP. Thus, ENPP1 blockade emerges as a unique target eliciting immune remodeling and leveraging the STING pathway. Several ENPP1 inhibitors have shown an immunostimulatory effect, and their combination with other therapeutic modalities, such as immune-checkpoint blockade, STING activation, DNA damage response (DDR) inhibitors, and radiotherapy (RT), represents a promising avenue to boost antitumor–immune responses and to improve current clinical outcomes in several tumors. This comprehensive review summarizes the current state of the art and opens new perspectives for novel treatment strategies.
Data from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
Authors: Sivapalan Lavanya , Iams Wade T. , Belcaid Zineb , Scott Susan C. , Niknafs Noushin , Balan Archana , White James R. , Kopparapu Prasad , Cann Christopher , Landon Blair V. , Pereira Gavin , Velculescu Victor E. , Hann Christine L. , Lovly Christine M. , Anagnostou Valsamo
Published: June 2023

AbstractPurpose:
Patients with small-cell lung cancer (SCLC) have an exceptionally poor prognosis, calling for improved real-time noninvasive biomarkers of therapeutic response.
Experimental Design:
We performed targeted error-correction sequencing on 171 serial plasmas and matched white blood cell (WBC) DNA from 33 patients with metastatic SCLC who received treatment with chemotherapy (n = 16) or immunotherapy-containing (n = 17) regimens. Tumor-derived sequence alterations and plasma aneuploidy were evaluated serially and combined to assess changes in total cell-free tumor load (cfTL). Longitudinal dynamic changes in cfTL were monitored to determine circulating cell-free tumor DNA (ctDNA) molecular response during therapy.
Results:
Combined tiered analyses of tumor-derived sequence alterations and plasma aneuploidy allowed for the assessment of ctDNA molecular response in all patients. Patients classified as molecular responders (n = 9) displayed sustained elimination of cfTL to undetectable levels. For 14 patients, we observed initial molecular responses, followed by ctDNA recrudescence. A subset of patients (n = 10) displayed a clear pattern of molecular progression, with persistence of cfTL across all time points. Molecular responses captured the therapeutic effect and long-term clinical outcomes in a more accurate and rapid manner compared with radiographic imaging. Patients with sustained molecular responses had longer overall (log-rank P = 0.0006) and progression-free (log-rank P < 0.0001) survival, with molecular responses detected on average 4 weeks earlier than imaging.
Conclusions:
ctDNA analyses provide a precise approach for the assessment of early on-therapy molecular responses and have important implications for the management of patients with SCLC, including the development of improved strategies for real-time tumor burden monitoring.

See related commentary by Pellini and Chaudhuri, p. 2176
Prognosis to Radiation Unlocked: How Hypoxia Methylome May Hold the Key in HNSCC
Authors: Heft Neal Molly E. , Brenner J. Chad
Published: June 2023

Hypoxia in head and neck tumors has proven to be predictive of outcomes. Current hypoxia signatures have failed for patient treatment selection. In a recent study, the authors identified a hypoxia methylation signature as a more robust biomarker in head and neck squamous cell carcinoma and shed light into the mechanism of hypoxia-mediated treatment resistance.

See related article by Tawk et al., p. 3051
Table 2 from Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Authors: Hamieh Mohamad , Mansilla-Soto Jorge , Rivière Isabelle , Sadelain Michel
Published: June 2023

Clinical trials investigating bispecific CAR T cells in B-cell malignancies and MM
Table 1 from Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Authors: Hamieh Mohamad , Mansilla-Soto Jorge , Rivière Isabelle , Sadelain Michel
Published: June 2023

FDA-approved CAR T cells
Supplementary Figures S1-S22 from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation
Authors: Sivakumar Smruthy , Moore Jay A. , Montesion Meagan , Sharaf Radwa , Lin Douglas I. , Colón Caterina I. , Fleishmann Zoe , Ebot Ericka M. , Newberg Justin Y. , Mills Jennifer M. , Hegde Priti S. , Pan Quintin , Dowlati Afshin , Frampton Garrett M. , Sage Julien , Lovly Christine M.
Published: June 2023

Figure S1: Patterns of tumor mutational burden across different ancestry groups.
Figure S2: Spectrum of TP53 and RB1 mutations in SCLC.
Figure S3: Gene alteration landscape detected from targeted sequencing of liquid biopsies.
Figure S4: Chromosomal loss events are frequent in SCLC and are preferentially enriched for tumor suppressor genes.
Figure S5: Hematoxylin & Eosin (H&E) staining for some representative SCLC tumors with rare genomic alterations.
Figure S6: Gene alterations detected in SMARCA4-altered SCLC.
Figure S7: SCLC tumors exhibit recurrent gene rearrangements with therapeutic potential.
Figure S8: Trends of overall survival across different ancestry groups and stage in the clinical cohort.
Figure S9: Examination of tumor purity and tumor mutational burden (TMB).
Figure S10: Liver and Brain SCLC metastases are enriched for chromosomal arm-level gains compared to lung-biopsied SCLC tumors.
Figure S11: SCLC tumors present with unique co-occurring and mutual exclusive patterns of gene alterations.
Figure S12: SCLC tumors with wild-type TP53 and/or RB1 have a low tumor mutational burden.
Figure S13: SCLC tumors with wild-type TP53 and/or RB1 present with specific gene alterations.
Figure S14: A smoking-associated mutational signature is rare in TP53/RB1 WT SCLC tumors.
Figure S15: TP53 and RB1 alterations are less frequent in never smokers.
Figure S16: Patterns of overall survival based on TP53 and RB1 alteration status.
Figure S17: TP53 and RB1 mutations are more frequent in older patients with SCLC.
Figure S18: Gene alterations detected in HPV-positive SCLC.
Figure S19: Examination of HPV subtypes and prevalence in TP53/RB1 mutant and wild-type SCLC tumors.
Figure S20: EGFR-mutant SCLC tumors exhibit unique mutational signature profiles.
Figure S21: No overall survival differences based on EGFR mutation status in SCLC.
Figure S22: Putative transformed SCLC tumors from EGFR-mutant NSCLC are enriched for EGFR exon 19 deletions.
Table S2 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
Authors: Aoki Kazunori , Nishito Yukari , Motoi Noriko , Arai Yasuhito , Hiraoka Nobuyoshi , Shibata Tatsuhiro , Sonobe Yukiko , Kayukawa Yoko , Hashimoto Eri , Takahashi Mina , Fujii Etsuko , Nishizawa Takashi , Fukuda Hironori , Ohashi Kana , Arai Kosuke , Mizoguchi Yukihiro , Yoshida Yukihiro , Watanabe Shun-ichi , Yamashita Makiko , Kitano Shigehisa , Sakamoto Hiromi , Nagata Yuki , Mitsumori Risa , Ozaki Kouichi , Niida Shumpei , Kanai Yae , Hirayama Akiyoshi , Soga Tomoyoshi , Maruyama Toru , Tsukada Keisuke , Yabuki Nami , Shimada Mei , Kitazawa Takehisa , Natori Osamu , Sawada Noriaki , Kato Atsuhiko , Yoshida Teruhiko , Yasuda Kazuki , Mizuno Hideaki , Tsunoda Hiroyuki , Ochiai Atsushi
Published: June 2023

Antibodies for FACS
TABLE 1 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
Authors: Aoki Kazunori , Nishito Yukari , Motoi Noriko , Arai Yasuhito , Hiraoka Nobuyoshi , Shibata Tatsuhiro , Sonobe Yukiko , Kayukawa Yoko , Hashimoto Eri , Takahashi Mina , Fujii Etsuko , Nishizawa Takashi , Fukuda Hironori , Ohashi Kana , Arai Kosuke , Mizoguchi Yukihiro , Yoshida Yukihiro , Watanabe Shun-ichi , Yamashita Makiko , Kitano Shigehisa , Sakamoto Hiromi , Nagata Yuki , Mitsumori Risa , Ozaki Kouichi , Niida Shumpei , Kanai Yae , Hirayama Akiyoshi , Soga Tomoyoshi , Maruyama Toru , Tsukada Keisuke , Yabuki Nami , Shimada Mei , Kitazawa Takehisa , Natori Osamu , Sawada Noriaki , Kato Atsuhiko , Yoshida Teruhiko , Yasuda Kazuki , Mizuno Hideaki , Tsunoda Hiroyuki , Ochiai Atsushi
Published: June 2023

Univariate and multivariate analyses of prognostic factors in LUAD and LUSQ
Fig. S7 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
Authors: Aoki Kazunori , Nishito Yukari , Motoi Noriko , Arai Yasuhito , Hiraoka Nobuyoshi , Shibata Tatsuhiro , Sonobe Yukiko , Kayukawa Yoko , Hashimoto Eri , Takahashi Mina , Fujii Etsuko , Nishizawa Takashi , Fukuda Hironori , Ohashi Kana , Arai Kosuke , Mizoguchi Yukihiro , Yoshida Yukihiro , Watanabe Shun-ichi , Yamashita Makiko , Kitano Shigehisa , Sakamoto Hiromi , Nagata Yuki , Mitsumori Risa , Ozaki Kouichi , Niida Shumpei , Kanai Yae , Hirayama Akiyoshi , Soga Tomoyoshi , Maruyama Toru , Tsukada Keisuke , Yabuki Nami , Shimada Mei , Kitazawa Takehisa , Natori Osamu , Sawada Noriaki , Kato Atsuhiko , Yoshida Teruhiko , Yasuda Kazuki , Mizuno Hideaki , Tsunoda Hiroyuki , Ochiai Atsushi
Published: June 2023

Number and percentage of immune cell types, CD4+ T cell subsets, CD8 T+ cell subsets, and myeloid cell type in respective immune subtypes. (a–d) Cell density and �45 of immune cell type (a), �4 of CD4+ T cell subset (b), �8 of CD8+ T cell subset (c), and %myeloid of myeloid cell type (d) are presented in respective immune subtypes of LUAD and LUSQ. ns; not significant. * p<0.05. **P<0.01. ***P<0.001. ****P<0.0001.
Fig. S17 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
Authors: Aoki Kazunori , Nishito Yukari , Motoi Noriko , Arai Yasuhito , Hiraoka Nobuyoshi , Shibata Tatsuhiro , Sonobe Yukiko , Kayukawa Yoko , Hashimoto Eri , Takahashi Mina , Fujii Etsuko , Nishizawa Takashi , Fukuda Hironori , Ohashi Kana , Arai Kosuke , Mizoguchi Yukihiro , Yoshida Yukihiro , Watanabe Shun-ichi , Yamashita Makiko , Kitano Shigehisa , Sakamoto Hiromi , Nagata Yuki , Mitsumori Risa , Ozaki Kouichi , Niida Shumpei , Kanai Yae , Hirayama Akiyoshi , Soga Tomoyoshi , Maruyama Toru , Tsukada Keisuke , Yabuki Nami , Shimada Mei , Kitazawa Takehisa , Natori Osamu , Sawada Noriaki , Kato Atsuhiko , Yoshida Teruhiko , Yasuda Kazuki , Mizuno Hideaki , Tsunoda Hiroyuki , Ochiai Atsushi
Published: June 2023

The relationship between TERT amplification and immune cell types in LUSQ. The correlations of the degree of TERT amplification with �45 of T, CD8+ T, mMDSC, and macrophage cells are plotted.
Fig. S13 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
Authors: Aoki Kazunori , Nishito Yukari , Motoi Noriko , Arai Yasuhito , Hiraoka Nobuyoshi , Shibata Tatsuhiro , Sonobe Yukiko , Kayukawa Yoko , Hashimoto Eri , Takahashi Mina , Fujii Etsuko , Nishizawa Takashi , Fukuda Hironori , Ohashi Kana , Arai Kosuke , Mizoguchi Yukihiro , Yoshida Yukihiro , Watanabe Shun-ichi , Yamashita Makiko , Kitano Shigehisa , Sakamoto Hiromi , Nagata Yuki , Mitsumori Risa , Ozaki Kouichi , Niida Shumpei , Kanai Yae , Hirayama Akiyoshi , Soga Tomoyoshi , Maruyama Toru , Tsukada Keisuke , Yabuki Nami , Shimada Mei , Kitazawa Takehisa , Natori Osamu , Sawada Noriaki , Kato Atsuhiko , Yoshida Teruhiko , Yasuda Kazuki , Mizuno Hideaki , Tsunoda Hiroyuki , Ochiai Atsushi
Published: June 2023

Relationship between immune subtypes and molecular subtypes. The molecular subtypes were analyzed by unsupervised consensus clustering of RNA-seq. The percentage of each molecular subtype in the immune subtype is plotted. The number of patients is specified in each column.